, an inhibitor of cdk4 and cdk6; or by reduction in the level of p27
Kip1 through haploinsufficiency or gene silencing. These are among the most commonly observed events in cancer cells.
The ARF tumor suppressor, encoded by the alternative reading frame of the INK4a / ARF locus, monitors mitogenic signaling through the ''Rb pathway.'' ARF is induced by abnormal growth -promoting signals, including overexpressed E2F and Myc or activated oncogenes, such as Ha -Ras or v -Abl. By antagonizing Mdm2, a negative regulator of the p53 tumor suppressor, ARF triggers a p53 -dependent transcriptional response. Therefore, when mitogenic signals reach an abnormal threshold, induction of the ARF -Mdm2 -p53 ''checkpoint'' diverts incipient cancer cells to undergo p53 -dependent cell cycle arrest or apoptosis, depending on the biologic context. Disruption of this form of cell -autonomous tumor surveillance through p53 mutation, Mdm2 overexpression, or ARF loss is also part of the life history of most, if not all, cancer cells. Because ARF modulates the balance between Mdm2 and p53, ARF loss not only dampens the p53 response to abnormal mitogenic signals but renders tumor cells resistant to p53 -dependent apoptosis induced by radiation or cytotoxic chemotherapeutic drugs. Recent data indicate that a number of transcription factors ( Twist, Bmi -1, JunD, Tbx -2, and others ) can affect p53 function by down -regulating ARF expression. At least some of these transcription factors may be involved in turning off the ARF checkpoint during embryonic development, when rapid cell divisions must be allowed to occur. By contrast, overexpression of Twist and Tbx -2 is observed in rhabdomyosarcoma and breast cancer, respectively. A prediction is that ARF deletion, silencing, and / or active repression will be most frequently observed in those tumors that retain wild -type p53 function and do not overexpress Mdm2.
If disabling the Rb and p53 signaling pathways is a hallmark of cancer, then the most efficacious treatment would be to restore their functions. The inability to specifically target genes to tumor cells and to properly regulate their expression makes gene therapy impractical. Novel therapeutics will likely need to target ancillary pathways. One rationale is based on the concept of ''synthetic lethality,'' in which disruption of one gene -in this case, those in the Rb or p53 pathways -might sensitive cells to disruption of another pathway while sparing cells that retain either of the two functions. Cyclin A -cdk2 activity is required to terminate S phase, and blocking this function triggers apoptosis. Cells that lack Rb or p53 might therefore prove more sensitive than normal cells to cdk inhibitors. Another approach would be to activate the apoptotic machinery ''downstream'' of those sensory signals that normally lead to p53 activation, for example by activating death -inducing receptors that couple directly to caspases.
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Heat shock proteins as key mediators of immune response to cancer Studies from our laboratory have uncovered three novel aspects of interaction of heat shock proteins ( HSPs ) and antigen presenting cells ( see 1 for review ). These observations show a key role for HSPs in adaptive and innate immunity and form the basis of creation of a new generation of vaccines against cancers, and infectious and parasitic diseases. The principles, demonstrated in mice, rats, frogs and humans, are: o Homogeneous preparations of HSPs gp96, calreticulin, hsp90 or hsp70 are associated with peptides derived from cellular proteins, incl. normal self proteins or mutated or foreign proteins ( 2 -5 ). o If HSPs ( which are actually HSP -peptide complexes ) are injected into immunocompetent hosts, the hosts develop potent antigen -specific CD8 + and CD4 + T cells ( 6, 7 ) . This response is directed solely at the altered or foreign peptides and not against self peptides not against the HSPs themselves. The immunogenic HSP -complexes may also be reconstituted in vitro from HSPs and synthetic peptides ( 5, 8 -10 ) . The mechanism of immunogenicity of HSP -peptide complexes is increasingly clear and involves the interaction of the HSPs with macrophage or dendritic cells through the CD91 HSPs receptors, followed by representation of the HSP -chaperoned peptides by the MHC I and MHC II molecules of the macrophage / dendritic cells ( 11 -13 ) . o HSPs stimulate macrophage and dendritic cells in a peptide -independent manner to secrete inflammatory cytokines and to express co -stimulatory molecules. HSPs also cause maturation of dendritic cells ( 14, 15 ) . It is our premise that HSPs play a central role in innate and adaptive immune responses including in indirect presentation and cross -priming.
A number of Phase I and Phase II trials have been carried out where patients with cancers of the colon, pancreas, kidney and melanoma have been treated with autologous cancer -derived gp96 and hsp70. Some trials have been completed ( see 16 for review ) while others including a Phase III trial are underway. The preliminary data from the human trials is consistent with the experience with experimental cancers of mice.
1. Srivastava, Menoret, Basu, Binder, and McQuade, Immunity, 8: 657 -665, 1998 2. Udono and Srivastava, Journal of Experimental Medicine, 178, 1391 -1396 , 1993 3. Ishii, Udono, Yamano, Ohta, Uenaka, Ono, Hizuta, Tanaka, Srivastava, and Nakayama, Journal of Immunology, 162: 1303 -1309 , 1999 4. Breloer, Fleischer, and von Bonin, Journal of Immunology, 162: 3141 -3147, 1999 O-3 T cell responses in cancer patients induced by tumour epitope -specific immune therapy Sherev Tumenjargal, Thomas Linnemann, Sylke Gellrich, Marcus Muche, Rodion Demine, Heike Audring, Katrin Sparbier, Ansgar Lukowsky, Gunda Herberth, Uwe Trefzer, Wolfram Sterry and Peter Walden Humboldt University Medical School Charité, Department of Dermatology, Berlin, Germany. Therapeutic vaccination with peptides representing tumour -associated T cell epitopes, with mimotopes or with hybrids of autologous tumour cells and allogeneic dendritic cells or activated B cells can induce substantial clinical effects in melanoma, renal cell carcinoma and cutaneous lymphoma patients such as long term stabilisation of the disease, tumour regression and, in some cases, complete response. These vaccination strategies aim at the induction or reactivation of tumour -specific cytotoxic T cells. To analyse the frequency and the magnitude of such responses peripheral white blood cells and tumour infiltrating lymphocytes ( TIL ) were analysed for the presence, frequency and phenotype of CD8 + T cells with specificity for the vaccination peptides or, in case of hybrid cell vaccination, for a panel of known melanoma -associated T cell epitopes. MHC -peptide -tetramers and intracellular IFN detection were employed in these analyses to differentiate antigen specificity and functional capacity of these cells. Epitope -specific T cells were isolated by magnetoseparation techniques and tested for their tumouricidal activity in vitro. The frequencies among the peripheral blood CD8 + T cells of cells with specificity for single tumour epitopes ranged after vaccination between 0.03% and 4%. The percentage of cells among these epitope specific T cells that were capable of mounting an effector response varied depending on antigen and patient between 20% and 80%. The remaining cells appeared to be anergic. Using five known melanoma associated T-cell epitopes, TIL were analysed for the frequency of tumourspecific cells. Up to 20% of the TIL responded to these peptides indicating that a high percentage of the TIL are tumour -specific and capable of responding against tumour -associated antigens. Extensive tumour antigen loss was found in patients who relapsed after initial response. Mimotope vaccination of patients with cutaneous T-cell lymphoma caused increased frequencies of circulating mimotope specific T cells and, clinically, initial complete responses in the two patients studied. One patient relapsed later and suffered from aggressive tumour growth which evolved into a leukaemia. Mimotope -specific T cell were found throughout the entire course of the disease and were tumouricidal when tested in vitro against the patients own tumour cells indicating that even during aggressive disease progression functional intact tumour -specific T cells were present in the patient that could recognise and destroy the tumour cells. The failure of the immune response to control tumour progression in this case correlates with increased levels of the immune suppressive cytokine IL -10 described for late -stage cutaneous lymphoma. In summary, the studies demonstrate that it is possible to induce effective antitumour immune responses in melanoma and cutaneous lymphoma patients. However, often relapses are observed after initial, sometimes complete responses that correlate with antigen loss, increasing frequencies of anergic T cells or with immune suppression.
O-4 DNA -based tumor vaccines induce strong tumor-specific immune responses Theresa L. Whiteside, PhD, Edward P. Cohen, MD, Andrea Gambotto, MD, and Joanna Stanson, MA University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA and University of Illinois School of Medicine, Chicago, IL 60612, USA. Development of anticancer vaccines is a major objective in our laboratories. A novel DNA -based vaccination strategy, combining several of the known requirements for generation of antitumor immune responses, namely, antigen presentation on dendritic cells ( DC ), allogeneic stimulation and IL -2 secretion, was evaluated in ex vivo experiments and in four different animal tumor models. The strategy is based on the principle that tumorassociated antigens ( TAA ) are products of mutated or dysregulated genes, which can be transferred from a tumor to another cell and stably expressed, altering the genotype and phenotype of the recipient cell. The vaccine is prepared by transferring tumor -derived DNA to a highly immunogenic fibroblast or tumor cell line ( ''master cell'' ), which is genetically modified to secrete IL -2 and which expresses both foreign class I MHC antigens and those shared with the donor of tumor DNA ( e.g., HLA -A2 ). As a proof -ofprinciple, DNA obtained from gp100 + melanoma was transfected by the calcium phosphate method into a gp100 À tumor cell. ELISPOT assays were used to show that the T-cell line specific for the gp100 epitope responded to the DNA recipient by IFN -Á secretion. In preclinical ex vivo studies, the DNA -based vaccine presented by DC to T cells obtained from the donor of tumor -derived DNA was shown to induce generation of autotumor -specific responses. In tumor -protection or tumor -therapy animal models, DNAbased vaccines induced tumor -specific immune responses and immunologic memory, leading to protection or tumor rejection, respectively, and significantly prolonged survival. On the strength of these preclinical results, we have designed a phase I clinical trial for patients with advanced recurrent oral carcinoma, who will receive a series of autologous tumor DNA -based vaccines following surgery. The primary endpoints are safety, toxicity and feasibility of generating the vaccine. The secondary objective is induction and evaluation of the immune responses against the autologous tumor. This vaccination strategy has several practical advantages: only small tumor biopsy is required for vaccine preparation, the number of DNA recipient cells can be expanded for multiple immunizations, and the semi -allogeneic vaccine stimulates immune responses to a broad array of TAA.
The ability of HIV-1 based vectors to transduce human monocytes, monocyte derived macrophages ( MDMs ) and dendritic cells ( DCs ) was examined, in order to develop an efficient protocol for antigen gene delivery to human antigen presenting cells. Freshly isolated monocytes were refractory to HIV-1 based vector transduction, but became infectable after in vitro differentiation to mature macrophages. This maturationdependent transduction was independent of the HIV-1 accessory proteins vif, vpr, vpu and nef in the packaging cells, or the central polypurine tract ( cPPT ) in the vector. The level and extent of reverse transcription of the HIV-1 based vector was similar after infection of either immature monocytes or mature macrophages. However, 2LTR vector circles could not be detected in monocytes, suggesting a block to vector nuclear entry in these cells. Transduction of freshly isolated monocytes exposed to HIV-1 based vector could be rescued by subsequent treatment with DC differentiation medium.
O-7
Reprogramming messenger RNA and protein function by spliceosome-mediated RNA trans -splicing (SMaRT )
M. Puttaraju, S. G. Mansfield, L. G. Mitchell, and M. A. Garcia -Blanco Intronn LLC, Raleigh, North Carolina, USA.
The functional repertoire of the human genome is amplified by the differential assortment of exons in the process known as alternative splicing. Spliceosome -mediated RNA trans -splicing ( SMaRT ) can similarly mobilize these exonic packets of genetic information to reprogram messenger RNAs. This emerging technology has applications in therapeutics, genomics and agrobiotech among other areas. We will present results that directly apply to gene therapy. In principle, SMaRT can repair defective transcripts in loss -of -function genetic disorders in humans. A readily tractable lacZ repair system was developed to serve as a model for these genetic disorders. Targeted pretrans -splicing RNA molecules ( PTMs ) efficiently and specifically repaired mutated lacZ transcripts. Most importantly, spliceosome -mediated RNA trans -splicing restored enzymatic activity to previously -galactosidase defective human cells. PTMs can be designed to repair terminal exons or to precisely replace internal exons in double trans -splicing reaction. The work on the lacZ system has now being extended to the repair of CFTR messenger RNAs and the restoration of CFTR function.
SMaRT can be used to conditionally express diphtheria toxin; toxin expression is dependent on trans -splicing to a HCG6 gene product that is specifically induced in tumor cells. We will present the development of internal exon reprogramming, or double trans -splicing, an application of SMaRT that because of high specificity is ideally suited for suicide gene therapy of neoplasms. The development of this work confirms the potential for spliceosome mediated RNA trans -splicing in gene therapy and provides a powerful tool for rational design and evolution of pre -trans -splicing molecules. Cancer gene therapy is faced with a specificity problem, i.e. the specific targeting of transgene expression to the site of the tumour. In view of the fact that the targeted transduction of genes still represents a major obstacle, the possibility to achieve high levels of transcription in specific cell populations through specific cellular promoters or regulatory elements is of particular interest. Frequently, tissue -specific or other selective promoters are inefficient activators of transcription, which severely limits their applicability. We developed a strategy, making use of a feedback loop, for improving promoter strength while maintaining specificity. Moreover, cell proliferation is one of the hallmarks of cancer cells that can be exploited for the targeting malignant tumours by gene therapy. It would be advantageous to achieve cell cycle dependence through the vector rather than the therapeutic gene. Two different strategies have been developed in the laboratory to accomplish this goal. The first approach is based on recently discovered mechanism of cell cycle -regulated transcriptional repression mediated by a repressor protein termed CDF -1. Based on this work, a dual specificity promoter system that combines cell type specificity with cell cycle regulation was developed. In the second approach the transgene is driven by an artificial heterodimeric transcription factor, whose DNA -binding subunit is expressed from a tissue -specific promoter, whereas the transactivating subunit is transcribed from a cell cycle -regulated promoter. As a result gene expression occurs preferentially in the proliferating cells of a specific type of tissue. 2 Paul -Ehrlich Institute, Paul -Ehrlich -Straße 51, 63225 Langen, Germany. Efficient and stable gene transfer into primary human T lymphocytes would greatly improve their use for adoptive transfer to treat acquired disorders, viral diseases, and cancer. Therefore, efforts have been undertaken to optimize gene transfer protocols to efficiently transduce primary human T lymphocytes. Most of these protocols rely on technical improvements which may lead to unpredictable alterations of T lymphocytes.
O-8 Dendritic cell dysfunction in cancer patients

O-10 Non viral gene delivery vectors
We have constructed retroviral vector pseudotypes of amphotropic murine leukemia viruses ( A -MLV, MLV-10A1 ), gibbon ape leukemia virus ( GaLV ), feline endogenous virus ( RD114 ), and vesicular stomatitis virus glycoprotein ( VSV-G ) containing the green fluorescent protein ( GFP ) as a marker gene. Using a RetroNectin -assisted transduction protocol and virus -containing supernatant, the MLV-10A1 pseudotype infected up to 85% of CD4 + T cell lines which then stably expressed GFP over time. More important, the MLV-10A1 pseudotype transduced both CD4 + and CD8 + T lymphocytes most efficiently in comparison with the other vector pseudotypes. The superior transduction efficacy of MLV-10A1 correlates with a longer half -life of this pseudotype in comparison with A -MLV. By viral interference analysis in the human T cell line HUT78 we show that MLV-10A1 can use both the A -MLV receptor Pit2 and the GaLV receptor Pit1 for cell entry. A similar result was obtained when a HIV-1 vector, encoding GFP, was pseudotyped with the different envelopes. Again, the MLV-10A1 pseudotype was superior in the transduction of primary Wnt ( Wingless / Int -1 ) signalling, active during mammalian embryogenesis, is specifically reactivated in nearly all human colorectal carcinomas and less frequently in a subset of other human malignancies ( e.g. hepatocellular carcinoma, desmoid tumours and melanomas ). Underlying this reactivation is the deregulation and nuclear accumulation of -catenin, which heterodimerizes with transcription factors of the LEF -1 / Tcf family to activate genes ( e.g. c -myc, cycD1 ) thought to contribute to carcinogenesis.
-catenin deregulation is largely due to mutation of the APC ( adenomatous polyposis coli ) protein which, as part of a multiprotein complex, normally targets -catenin for degradation. Although observed less frequently, mutation of -catenin itself, can result in the same outcome.
As part of a novel approach to achieving tumour -specific gene expression we generated an artificial -catenin -dependent promoter ( ''CTP1'' ) consisting of multiple -catenin / Tcf binding sites combined with a basal promoter ( SV40 ). In transient luciferase reporter studies, CTP1 activity was comparable to CMV in tumour cell lines with deregulatedcatenin ( SW480 [ mt APC ] and HepG2 [ mt -catenin ] ) but 30 -70 -fold lower in cells in which -catenin regulation is intact ( HeLa ). To explore the utility of CTP1 in more detail we constructed E1 -deleted recombinant Ad5 vectors containing either a lacZ reporter ( ''Ad.CTP1 -LacZ'' ) or the E. coli Nitroreductase ( NTR ) gene ( ''Ad.CTP1 -NTR,'' [ CTL501 ] ), driven by CTP1. Both the activity and -catenin -dependence of CTP1 were retained within these Ad vectors. Intratumoural injection of CTL501 or of a control virus containing Ad.CMV-NTR resulted in equivalent sensitisation to the prodrug CB1954 in permissive xenografts. In contrast, Ad.CTP1 -LacZ was approximately 3 orders of magnitude less active than Ad.CMV-LacZ in human primary hepatocytes and HUVECs. To assess the activity of CTP1 in primary and secondary colorectal cancers, freshly excised tumour material was incubated in Ad.CTP1 -LacZ and Ad.CMV-LacZ and LacZ -expressing cells visualised by X -Gal staining. CTP1 was strongly active in 6 / 8 primary and 3 / 3 secondary tumours. Current studies indicate that the specificity of CTP1 can be improved without loss of activity. The use of a modified CTP1 promoter, ''CTP3,'' to obtain cancer -specific adenovirus replication will be discussed.
Keywords For efficient and versatile use of Adenovirus ( Ad ) as an in vivo tumor therapy vector, modulation of the viral tropism is highly desirable. To meet this requirement, a novel method to genetically alter the Ad fiber tropism was developed. The knob and the 15 last shaft repeats of the fiber gene were deleted and replaced with an external trimerisation motif and a new cell binding ligand, in this case the integrin -binding motif RGD. The corresponding recombinant fiber retained the basic biological functions of the natural fiber, i.e. trimerisation, nuclear import, penton formation and ligand binding. The recombinant fiber bound to integrins, but failed to react with anti -knob antibody, as expected. For virus production, the recombinant fiber gene was rescued into the Ad genome at the exact position of the wild type ( WT ) fiber to make use of the native regulation of fiber expression. The recombinant virus Ad5 / FibR7 -RGD yielded plaques on 293 cells, but the spread through the monolayer was 2 -3 times delayed compared to WT, and the ratio of infectious to physical particles was 20 times lower. Studies on virus tropism showed that the recombinant virus was able to infect cells which did not express the Coxsackie Adenovirus Receptor ( CAR ), but expressed integrins. Thus, Ad5 / FibR7 -RGD virus showed an expanded tropism, which is useful for applications where gene transfer to cells not expressing CAR is needed.
However, when complex ligands such as single chain antibody fragments were used to replace the RGD motif, it was found that such fibers were neither able to assemble into functional pentons in vitro in the presence of penton base, nor to be rescued into infectious virions. The limiting factor seems to be the ability of the new cell binding ligand to fold correctly in the cytoplasm where the fibers are synthesized. Ligands that cannot fold correctly in the reducing cytoplasmic environment are often only partly soluble and may confer inability on the recombinant fibers to form trimers and assemble into pentons. In addition, incorrect ligand folding will reduce or abolish binding of the corresponding virus to the selected cellular receptor. It was therefore necessary to identify novel cell binding ligands that can be properly folded in the cytoplasm of virus producing cells.
We could show that the coding sequence for a three -helix bundle domain structure Z, derived from the Ig binding Staphylococcal protein A, can be functionally incorporated into the modified knobless Ad fiber gene and yields functional virions, with an expected Fc binding capability which also could be employed for viral entry into 293 cells engineered for Fc surface expression. Through combinatorial protein engineering targeted to surface located residues of the Z domain, libraries of this domain have been constructed from which variants with novel binding specificities, so called affibodies, have been selected using conventional phage display -panning ( Nord et al., 1997 ) . In the present work, viruses have been constructed where each virus fiber carry one or even two different functional affibodies. We conclude that affibodies seem uniquely suited for the construction of genetically retargeted Ad and may become important ligands in this field, and that, based on the findings described here, functional, genetically retargeted viruses can be made using ligands capable of correct folding in the mammalian cell cytoplasm. ] MIBG to RSV / NAT / UVW and hTERC / NAT / UVW spheroids respectively. The activity of the hTERC promoter was upregulated by administration of 2 Gy gamma irradiation, as determined by a 30% enhancement of MIBG uptake, 24 hours after irradiation.
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Conclusions: Transfection of the NAT transgene under the control of the RSV and hTERC promoters into UVW glioma cells, endowed them with the capacity for active uptake of [ 131 I ] MIBG. hTERC driven NAT expression resulted in MIBG uptake levels of 70% that achieved utilising the RSV promoter. Further, the hTERC promoter expressed NAT at sufficiently high levels to allow total sterilisation of hTERC / NAT / UVW spheroids at [ 131 I ] MIBG doses only slightly higher that those required for sterilisation of the RSV / NAT / UVW spheroids. Additionally, hTERC promoter activity was upregulated by gamma irradiation. These data suggest that hTERC is a strong promoter which has potential for tumour specific cancer gene therapy strategies. Further studies are underway to assess the specificity of this promoter and the human telomerase protein component promoter, hTERT.
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The new era of molecular targets for cancer therapy Joe B. Harford, PhD Associate Director for Special Projects, National Cancer Institute, Bethesda, MD 20892. E-mail address: ( harfordj @nih.gov ). The National Cancer Institute's goal is to stimulate and support scientific discovery and its application to achieve a future when all cancers are uncommon and easily treated. NCI works toward this goal by providing vision to the cancer research effort in the United States and leadership for thousands of NCI -funded researchers across the United States and around the world. NCI has identified six areas of extraordinary scientific opportunity in cancer research through formal input from cancer scientists, educators, advocates, and community leaders. Among these extraordinary opportunities are two related topics. The first is termed Defining the Signatures of Cancer Cells: Detection, Diagnosis, and Therapy. NCI's goal in this area of extraordinary opportunity is to generate a complete catalog of distinguishing molecular profiles of normal, precancerous, and cancer cells at all stages and in all tissues, and use the catalog to: ( a ) develop diagnostic techniques for the earliest detection of precancerous lesions and cancers; ( b ) develop signature -based therapies; and ( c ) identify subsets of patients with different prognoses to predict therapeutic response. The second set of initiatives is termed Molecular Targets of Prevention and Treatment. Many existing anticancer agents inhibit the growth of cancer cells successfully, but they also affect healthy cells, causing short -and long -term toxic effects that can themselves endanger patients' health and quality of life. But advances in cancer biology, chemistry, and technology are providing the knowledge and tools to develop a whole new generation of cancer treatments and preventives that attack essential tumor cell processes with greatly reduced side effects. NCI's goal is to accelerate the discovery, development, and testing of prevention and treatment agents that target the molecular changes underlying various stages of cancer initiation and progression. NCI's Home Page hwww.cancer.govi offers a more comprehensive description of NCI's priorities, plans, and programs as well as contact information for NCI staff associated with these activities. A nonviral systemic delivery system has been optimized in our laboratory for targeted gene therapy of cancer. This new gene delivery system homes to tumor cells owing to elevated levels of the transferrin or folate receptor on their surface. This system has been shown to be relatively tumor -specific since the expression of the exogenous gene was found in both the primary tumor and metastasis, and not in the normal organs such as liver, lung, muscle, bone marrow and intestinal crypts.
Loss of normal p53 function has been associated with resistance to both chemotherapy and radiotherapy. In in vitro and in vivo experiments, we have stepwise proved in principle that the restoration of the normal tumor suppressor gene p53 ( wtp53 ), by means of this nonviral, liposome -based, tumor -targeted complex, renders the tumor cells more sensitive to the induction of apoptosis by conventional chemotherapeutic agents or radiation in prostate, head and neck ( SCCHN ), breast and other tumor models. We have reproducibly demonstrated, in vivo, that when the wtp53 liposomes were injected i.v., preexisting prostate cancer and SCCHN xenografts completely regressed after radiotherapy. Mice stayed tumor free for as long as eighteen months post -treatment. Our studies in breast cancer cells showed a greater than 10 -fold increase in sensitization to a number of chemotherapeutic agents in cells treated with this complex. In a metastasis model ( MDA -MB -435 ), we observed a significant improvement in survival when the combination of systemic delivery of wtp53 and doxorubicin was administered. In a syngeneic mouse melanoma metastasis model, B 16 / F 10 , we observed elimination of the lung metastases when the targeted wtp53 liposomes were combined with cisplatin.
The sensitization of tumors and metastasis to chemotherapy and radiation could result in lowering the effective dose of either anticancer agent, correspondingly lessening the severe side effects, while decreasing the possibility of recurrence. Moreover, this approach can be applied to both primary and recurrent tumors as well as metastatic disease. This is a novel strategy combining molecular medicine with currently used chemotherapy and radiotherapy for the treatment of cancer. The systemic delivery of normal tumor suppressor gene p53 by a nonviral, ligand -targeted, liposome delivery system as a new therapeutic intervention has the potential to critically impact the clinical management of cancer.
O-19 Enhancing cancer apoptosis in therapeutic design
Wafik S. El -Deiry Department of Medicine, Genetics and Pharmacology, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. A detailed understanding of the signaling events involved in programmed cell death in cancer versus normal cells is essential for the derivation of novel targets for therapeutic design. The identification of targets of tumor suppressor genes such as p53 or BRCA1 or components of the TRAIL signaling pathway is providing mechanistic insight into the pathways of growth arrest, repair and apoptosis. Recent experiments in my laboratory have provided evidence for tissue -specific patterns of p53 -target gene activation during apoptosis, a finding that has therapeutic implications. Our ongoing studies of BRCA1 have recently focused on interactions with the p53 pathway and have revealed a unique BRCA1 -dependent p53 transcriptional response leading to DNA repair, cell cycle arrest but not apoptosis. The targets involved in this transcriptional response represent novel direct connections between BRCA1 and DNA repair providing a new model and could be exploited for therapeutic benefit. Finally, in studies of the TRAIL signaling pathway, which is in part regulated by p53, we have identified a novel caspase regulatory protein which is providing insights into the extrinsic pathway of cell death and which may be an attractive target for drug design.
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Adenovirus vectors with complex regulation of FasL expression for prostate cancer gene therapy In previous studies we have shown that intratumoral delivery of proapoptotic FasL -GFP fusion gene using an adenovirus vector can force cells of several cancer types into apoptosis. However, FasL activity is also toxic to many normal tissues and severe liver damage can occur if the vector escapes into circulation. To apply this strategy to localized prostate cancer therapy, it is highly desirable to limit or eliminate cytotoxic gene expression in normal cells, while maximizing it in tumor cells. While natural and synthetic prostate -specific promoters are available, they range from weak to moderately active. By using ARR2PB promoter to direct FasL -GFP expression, we are able to completely limit expression and cytotoxicity to prostate cancer LNCaP cells. However, although ARR2PB is one of the strongest synthetic prostate -specific promoters, apoptotic activity generated with this vector is substantially lower than that achieved with constitutive promoters such as CMV. To further increase the therapeutic potential of prostate -specific FasL expression, we have developed a complex adenoviral vector that combines prostate cell specificity with high expression levels and the ability to regulate that expression. In this system, we have placed the tetracycline transactivator gene under the control of the ARR2PB promoter, and a FasL -GFP gene under the control of the tetracycline responsive element. The latter expression cassette was inserted into the cloning site near the right ITR of Ad5, to minimize background transgene expression. In this design, the level of prostate -specific FasL -GFP expression is amplified by binding of the transactivator to the tet -responsive promoter. We demonstrate that the levels of FasL -GFP expression generated by the complex vector are much higher than those achieved by the ARR2PB promoter directly. Using this prostate -specific / tet -regulated system, we can efficiently induce apoptosis of LNCaP cells that are resistant to lower levels of FasL expression. Moreover, high expression levels are observed only in LNCaP cells and not in cells of other origins. Expression levels in LNCaP cells can be regulated by the addition of doxycycline to culture medium. Systemic vector delivery studies in a CD -1 mouse model confirm that both the ARR2PB and the prostate -specific / tet -regulated vectors are well tolerated at doses that are lethal for vector with CMV driven FasL -GFP expression. Histological analysis of liver cryosections has revealed very little tissue damage, and in situ TUNEL assay detected minimal levels of vector -related apoptosis. This study demonstrates the feasibility of substantially increasing the activity of cell type -specific promoters in order to achieve both highly effective and safe Ad vectors for gene therapy of cancer.
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An anti -vascular approach to gene therapy: exploiting hypoxia relatively few blood vessels. The group is studying a number of ways to target a retroviral vector to the endothelial cells of tumour blood vessels and to limit extraneous expression. As part of this approach, the tumour -specific phenomenon of transient hypoxia in the microvasculature was exploited to target transcription. Previous studies have shown that a trimer of hypoxic response elements ( HREs ) from the phosphoglycerate kinase -I gene placed in a Moloney murine leukaemia viral LTR strongly induces expression in hypoxia compared to normoxia. We have similarly replaced the 3 0 LTR enhancer with this HRE trimer and confirmed these results. Histochemical titre was reduced 100 -fold in normoxia, equivalent to enhancer deletion, but expression was strongly induced in 0.5% oxygen. A construct with a mutated HRE did not respond to hypoxia and behaved similarly to the vector with a deleted enhancer. In addition, a 6 -mer of HREs gave even higher levels of enzyme production and fully restored histochemical titre. Different cell types differed in their response to hypoxia and in the induction kinetics. LTR hybrid vectors incorporating HREs adjacent to endothelial -specific promoters were constructed to see if the HREs could provide a further level of specificity for hypoxic endothelial cells. Preliminary results of the behaviour of these constructs are shown here.
O-22
Adenovirus -mediated E2F1 gene transfer enhances therapeutic efficacy of gemcitabine in pancreatic cancer Pancreatic cancer is an extremely malignant, rarely curable disease. Less than 20% of patients are suitable candidates for surgery, and for the remainder palliative chemotherapy is of only marginal benefit. A critical determinant of the efficacy of antineoplastic therapy is the ability of malignant cells to undergo apoptosis in response to DNA damage induced by cytotoxic agents. As a cause of chemoresistance, the lack of functional p53 which is mutated in up to 70% of pancreatic adenocarcinomas has been proposed to be a component of the inhibition of apoptosis. Thus, modulation of the apoptotic pathway represents a logical target for therapeutic intervention. We evaluated the antitumoral capacity of E2F1 either alone or in combination with the nucleoside analogue gemcitabine on the growth of p53 -null or mutant pancreatic tumor cell lines. Recently, gemcitabine compared to other antipancreatic drugs has been shown to produce a clinical response in 30% of patients with unresectable pancreatic tumors. In all cell lines tested, the adenovirus -mediated transfer of exogenous E2F1 in combination with gemcitabine treatment resulted in a strong induction of apoptosis, whereas the effect of either therapy alone varied between different cell lines. Interestingly, sensitization of pancreatic cancer cells for apoptosis induced by combination treatment was directly correlated with the induction of p73. In nude mice, injection of a helper -dependent adenovirus vector expressing E2F1 ( HD -AdE2F1 ) into subcutaneously induced MZA tumors resulted in a significant reduction of the tumor volume only in combination with gemcitabine. These data provide the first evidence that the recently discovered E2F1 / p73 pathway is an important target for the treatment of pancreatic tumors lacking functional p53.
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Rae -1 recognition by NKG2d: a molecular mechanism for T-cell mediated surveillance of cutaneous malignancy in the mouse It has long been suggested that developing tumors might be under surveillance by cells of the immune system, where antigens not conventionally present in normal or uninfected tissues trigger a danger response in hope of preventing dissemination. Consistent with this notion, we demonstrate that mice genetically lacking the capacity to generate T lymphocytes are rendered more susceptible to the development of cutaneous malignancy, a finding underscored by the increased prevalence of squamous cell carcinomas in immunosupressed transplant recipients. Interestingly, mice specifically lacking the enigmatic T-cells developed a higher incidence and progression of skin lesions induced by three independent means. T-cells are thought to comprise a ''first line of defense'' as they are commonly enriched in peripheral tissues and embedded within epithelial layers. As they have limited receptor chain diversity and are not commonly found in areas of diverse antigen sampling, it had been proposed that these cells recognize generic indicators of stress rather than specific foreign antigens, and that a good candidate for such a signal would be class Ib MHC molecules. Two human molecules fitting this bill, MICA and MICB, have previously been found to activate T cells isolated from tumors of the human colon, by binding to the NKG2d receptor. MICA / B expression is normally restricted to gastrointestinal epithelium but is elevated in many epithelial tumors and derived cell lines and is regulated by a heat shock promotor insuring inducible expression under specific stresses. Although mice lack the genes for MICA / B, the NKG2d receptor gene, which is also expressed by a spectrum of other cytolytic cells, is highly conserved. We demonstrate its binding to an inducible murine class Ib MHC molecule, Rae -1, previously identified only in the embryo but now shown to be elevated in a variety of transformed cells. Despite differences, the similarities in structure, expression and biological effect lead us to believe Rae -1 is a murine equivalent of MICA.
Our data demonstrate a molecular mechanism whereby local T-cells can stem early events in tumor formation by responding to elevated levels of Rae -1 or a second ligand for NKG2d, H60, at the site of oncogenesis. With no evidence for presentation of any peptide or antigen, or need for an activating modification, Rae -1 is thought to target a cell for destruction by tipping the normal balance of inhibitory and activatory signals. This makes Rae -1 an attractive candidate for cancer immuno gene therapy if coupled with tumor targeting vectors to drive overexpression in cancer cells or growing endothelium. Moreover, there is increasing weight placed on early lytic and inflammatory events mediated by NK and cells for effective uptake and presentation to the systemic adaptive immune system. Thus, NKG2d mediated killing could make visible peptide epitopes from mutated oncogenes and overexpressed proteins which vary diversely among cancers being a general means to get a custom tumor vaccine. Furthermore, since the NKG2d receptor is present also on, CD8 T-cells, NK cell, and activated macrophage, and has been shown to provide co -stimulation for human T-cells, Rae -1 will likely enhance latter stages of the immune response. The identification of NKG2d ligands in the mouse which parallel human biology will enable further study and novel approaches to tumor immunotherapy or gene therapy in experimentally tractable murine models of human cancer.
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Strategies for adenoviral vector mediated therapy of estrogen dependent tumors and melanoma CONFERENCE ABSTRACTS these issues, our laboratory has been studying the use of the L -plastin promoter, to confer tumor specific gene expression and conditional replication competency on adenoviral vectors which is truly tumor specific. John Leavitt first reported that the L -plastin gene, which encodes an actin binding protein found only in normal leukocytes and in no other tissue, was expressed at high levels in most established tumor cell lines. Injae Chung of our laboratory placed a truncated 2.5 kb form of the L -plastin promoter 5 0 of the LacZ gene in a replication incompetent adenoviral vector and showed expression of the LacZ gene in established cancer cell lines and in explants of ovarian cancer, but no expression in explants of non -neoplastic tissue. XY Peng then showed that this L -plastin promoter could drive the expression of the cytosine deaminase gene in replication incompetent adenoviral vectors in a tumor specific manner, thereby sensitizing these tumor cells but not non neoplastic cells to the effects of the prodrug 5 -fluorocytosine. Lixin Zhang then placed the L -plastin promoter 5 0 of the E1A gene in a wild type adenovirus ( Ad -Lp -E1A ). In a separate construction, he placed the tyrosinase promoter and enhancer 5 0 to the E1A gene ( Ad -Tyr -E1A ). He showed a correlation between the expression of E1A in neoplastic and non neoplastic cell lines and cytotoxicity in cell lines exposed to the Ad -Lp -E1A and the Ad -Tyr -E1A vectors, which generated lysis in cancer cell lines derived from estrogen dependent tissue and melanoma cells respectively. In addition, the Ad -Lp -E1A vector was 1000 times as toxic to explant cultures of ovarian cancer cells as was a negative control replication incompetent adenoviral vector carrying a CMVLacZ transcription unit in place of the E1A gene. The recombinant adenoviral vector containing extra cellular domain of mouse Flt3L ( AdmFL ) was constructed using a simplified bacterial homologous recombination system. C57BL / 6 mice were inoculated subcutaneously with hepa 1 -6 cells and allowed to growth for three weeks. The mice bearing tumor lesion at 5Â5 mm and 10Â10 mm were chosen for experiments. Tumor bearing mice received either a single intratumoral injection of 1Â10 9 efu AdmFL or a same dose of intratumoral injection of AdmFL followed by a systemic sublethal 5 -FU chemotherapy ( 10 mg / kg, three times a week for two weeks ). Mice received a systemic administration of 5 -FU and intratumoral injection of adenovirus without insert of Flt3L were used as controls. A single intratumoral injection of AdmFL greatly inhibits tumor growth in 75% of mice and also, is effective to protect tumor -free mice from parental tumor cell challenge but not from EL -4 cells, a syngenic lymphoma cell 
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Deciphering the mechanism of the bystander effect in Fas ligand gene therapy James S. Norris, Marc Hyer, Sunil Sudarshan, Christina Voelkel -Johnson, Charles Chalfant, Jian -Yun Dong, Yusuf Hannun Medical University of South Carolina, Charleston, South Carolina, USA. Currently, human gene therapy protocols for treatment of cancer are hampered by the efficacy of delivery systems available for human use. Thus, presently we lack the means to deliver a corrective ( or lethal ) gene to every cell resident in a tumor. There are several possible solutions to this problem. First, many laboratories are engaged in developing better delivery systems. Second the development of metabolic enzymes that act by metabolizing prodrugs to toxic metabolites results in bystander killing thus abrogating the necessity of 100% delivery. Third a similar approach is to harness the power of genes to induce apoptosis and some of these genes also generate bystander activity. The bystander effect is defined as when the number of dying cells in the tumor is greater than the number of cells effected. The mechanism of this is under study but has remained elusive. We have addressed this question by using AdGFPFasL infection of prostate cancer cells which overcomes their innate resistance to exogenous Fas ligand ( FasL ) ( Hyer et al. Mol. Therapy 2000 ) and leads to apoptosis. Fractionation of the apoptotic vesicles and media have lead to the discovery that the GFPFasL fusion gene as well as high levels of ceramide are present in the vesicles. Recently, Kolesnick's group ( Cremesti et al., Ceramide Enable Fas to Cap and Kill, JBC April 3, 2001 manuscript M101866200, JBC website ) published that in cells resistant to Fas signaling because of lack of capping, restoration of capping was possible by applying 25 nM doses of C16 -ceramide. We have confirmed experimentally that our vesicles both express FasL and contain high levels of ceramide and are capable of causing apoptosis. Further it appears apoptosis is mediated in concert by both GFPFasL / shFasL and ceramide. The basis for ceramide production in the dying cells is under study. However, by mass spectrometry we see substantial amounts of dihydroceramide suggesting ceramide synthase ( de novo synthesis ) is playing a major role. Since anthracyclines used in prostate cancer gene therapy are reported to elevate ceramides in prostate we hypothesize that adGFP -FasL gene therapy, coupled with low dose anthracyclines or ceramidase inhibitors, will enhance tumor cell death and provide a new approach to treatment of prostate cancer.
Supported by NIH CA69598.
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A novel enzyme /prodrug system for hypoxia -and radiation -regulated suicide gene therapy X -rays induced an increase in sensitivity of HRP -expressing cells of 2.5 -2.6 ( 0.1 mM IAA ) and 5.4 -5.6 ( 0.5 mM IAA ). Delivery of the HRP gene itself or exposure of HRP À cells to IAA did not affect the response to radiation. To specifically target the radio -and chemoresistant population in solid tumours, the HRP gene was placed under the control of hypoxia -or radiation -responsive promoters. Five copies of hypoxia -regulatory elements ( HREs ) from the PGK -1 or the EPO genes were inserted upstream of the basal cytomegalovirus promoter. After 24 -h hypoxic incubation, the EPO and the PGK -1 HREs induced a 30 -40 -fold and a 5 -6 -fold increase in HRP expression respectively. Transfection with the EPO -HRP construct conferred hypoxia -selective sensitivity to IAA and analogues. HRP production in irradiated cells was achieved by using radiation -responsive CArG elements ( Marples et al. Gene Therapy. 7: 511, 2000 ) . After 5 Gy Xirradiation, a selective 2 -3 -fold increase in transgene expression was detected.
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Adenoviral delivery of p53 gene suppresses expression of collagenase -3 ( MMP -13 ) in squamous carcinoma cells
Risto Ala -aho, Reidar Grenman*, Prem Seth # , Veli -Matti Kähäri Turku Centre for Biotechnology, University of Turku and Å bo Akademi University, Departments of Medical Biochemistry and Dermatology, University of Turku, Turku, Finland; *Department of Otorhinolaryngology, Turku University Central Hospital, Turku, Finland. Squamous cell carcinomas ( SCCs ) of the head and neck are malignant tumors with high ability to invade locally and metastasize to lymph nodes. SCC cells express several matrix degrading metalloproteinases ( MMPs ) and they often harbor mutations in p53 tumor suppressor gene. Collagenase -3 ( MMP -13 ) is specifically expressed by SCC cells and it is thought to play an important role in their invasion and metastasis. We have used recombinant adenovirus harboring wild type p53 gene to examine the effect of p53 on MMP -13 and MMP -1 expression in cutaneous SCC cell lines, which have different p53 status. One SCC cell line, in which one p53 allele is mutated, resulted in potent inhibition of MMP -13 production ( by 85 to 90% ) 24 and 48 h after adenovirus -mediated delivery of p53. In the same cells, production of collagenase -1 ( MMP -1 ) was suppressed by 50%, while production of gelatinase -A ( MMP -2 ) and gelatinase -B ( MMP -9 ) was not altered in response to expression of exogenous wild type p53. Furthermore, infection of SCC cells with RAdp53 resulted in marked reduction in their invasion capacity through Matrigel. Expression of cyclindependent kinase inhibitor p21 / Waf1 / Cip1 was induced as a marker of p53 expression after 24 h, whereas p27 / Kip1 expression was not altered. Apoptotic cells were not seen 24 h after p53 delivery, whereas after 48 h apoptotic cells were detected by Hoechst staining. A SCC cell line, harboring wild -type p53 but lacking p21 / Waf1 / Cip1, showed also potent MMP -13 inhibition regardless of lack of p21 / Waf1 / Cip1. These results show, that wild type p53 potently and specifically inhibits expression of MMP -13 by SCC cells independent of its proapoptotic effect and p21 / Waf1 / Cip1 expression. Together these results show, that p53 exerts a biphasic tumor suppressor effect on SCC cells: early inhibition of invasionrelated proteinase, MMP -13, and late induction of programmed cell death. Reproducible evidence of viral replication was obtained ( within < 10 days ) following 1 ) i.t., i.a. and i.v. administration, 2 ) in head and neck and colorectal cancer patients but not in pancreatic ( i.t. ) or ovarian ( i.p. ) carcinomas; no patient had replication documented > 10 days after treatment. Single agent -induced objective tumor regressions were demonstrated in head and neck cancers ( 15 -20% ) but not in pancreatic, colorectal, ovarian or metastatic lung tumors. Evidence for potential synergy with chemotherapy has been obtained from head and neck ( i.t. ) and colorectal cancer patients ( i.a. ) ( 5 ) ( 6 ). IL -1, IL -6, IL -10, interferon -gamma and TNF levels all increased acutely following i.a. and / or i.v. administration ( 6 ) ( 7 ).
Given the clear documentation of safety and feasibility with this approach following intravascular administration, but the lack of significant single agent efficacy to date with dl1520, we carried out preclinical studies of intravenous treatment with a significantly more potent adenovirus dl922 / 947 ( E1A mutant ) in nude mouse -human tumor xenograft models; antitumoral efficacy was significantly superior to dl1520 in all models, and equivalent to or even superior to wildtype adenovirus i.v. The replication -selective virus approach has promise as a systemic treatment for cancer.
Acknowledgements Hepatocellular carcinoma is one of the most common tumours worldwide. The prognosis of hepatocellular carcinoma is poor and current therapies are largely ineffective. Genetic abnormalities are commonly seen in hepatocellular carcinoma tumours in particular with inactivation of p53 tumour suppressor gene. Gene therapy with E1B deleted ( dl1520 ) adenovirus could be of therapeutic value as it offers the potential of tumour growth control in patients with p53 mutations. Ten patients with post -hepatitis cirrhosis and histologically proven hepatocellular carcinoma were entered into an open label, randomised prospective study.
Patients were randomised to receive either percutaneous ethanol injection or E1B deleted adenovirus. Toxicity and complications in the ethanol group were pain and fever, while in the gene therapy group complications were minimal. Grade I -II toxicity fever, stable performance status and no significant rise in liver enzymes were observed in patients treated with E1B deleted adenovirus.
Analysis of patients' response to treatment in the gene therapy group showed one patient with a partial response and four patients with progressive disease. In the ethanol treated group 2 patients had stable disease and 3 patients showed disease progression. In conclusion this study showed that the adenovirus was well tolerated, but did not seem to offer significant tumour control in patients in this study. More effective vectors are needed in order to achieve a useful clinical impact. 
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Designing effective strategies to load human dendritic cells ( DC ) with tumor antigens is a challenging approach for DC -based tumor vaccines. We developed a mRNA -based electroporation technique to efficiently introduce tumor antigens into DC. After optimization of mRNA electroporation in K562 cells, high -level transgene expression ( 60 -80% transfected cells with only 5% cell mortality after transfection ) was obtained in human monocyte -derived DC ( Mo -DC ), CD34 + progenitorderived DC and Langerhans cells, as determined by EGFP reporter gene analysis. Then, we tested this technique as a potential strategy for tumor antigen loading of DC. Importantly, DC electroporated with mRNA encoding the Melan -A melanoma antigen were able to activate a Melan -A -specific cytotoxic tumor -infiltrating lymphocyte ( TIL ) clone in an HLA -restricted manner. Interestingly, maturation of DC after mRNA electroporation lead to a significant increase in TIL activation. Our data clearly demonstrate that Mo -DC electroporated with mRNA present functional antigenic peptides to cytotoxic T cells in an efficient manner. In an influenza model system, we show that matrix protein M1 mRNAelectroporated DC can efficiently induce an MHC class -I restricted immune response in vitro. Furthermore we examined gene expression and stimulatory capacity of cryopreserved mRNA -electroporated DC. We show that cryopreserved M1 mRNA -electroporated mature DC retain stimulatory capacity and can specifically activate autologous influenzaspecific T cells. All these data suggest that mRNA -based electroporation of DC represents a powerful loading strategy for future DC -based cancer vaccines. Currently this strategy will be examined in different tumor models.
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High efficiency gene transfer into human monocytederived dendritic cells by mRNA electroporation Tuyaerts Sandra, Noppe Sofie, Corthals Jurgen, Heirman Carlo, Carels Danny, Huysmans Christine, Vaeremans Elsy, Thielemans Kris Laboratory of Physiology, Medical School, VUB, Laarbeeklaan 103 / E, 1090 Brussels, Belgium. E-mail address: kthielem@fysp.vub.ac.be. Dendritic cells ( DC ) are the most potent antigen presenting cells of the immune system. At an immature stage, DC are specialized in internalizing and processing antigens, subsequently they migrate to lymphoid organs and undergo a maturation step. During maturation, DC upregulate costimulatory molecules ( CD80, CD86 ) and DC -specific markers ( CD83 ). These mature DC are fully equipped to present antigenic epitopes to CD4 + and CD8 + T lymphocytes, in order to induce an antigen -specific T cell response. As a Cancer Gene Therapy, Vol 8, No 11, 2001 consequence, the use of genetically modified DC is a promising approach in cancer immunotherapy.
Several strategies have been explored to deliver genes into DC, which can be divided into two groups: viral and nonviral strategies. Until now, the viral approaches turned out to be more efficient compared to nonviral systems, but safety concerns for their use in immunotherapy remain an important issue.
Among the numerous nonviral strategies to load DC with antigen, we mention proteins or peptides, pulsing with RNA or DNA, lipofection of RNA or DNA, and exposure to tumor cell lysates or apoptotic bodies from tumor cells.
In this study, we describe a method in which the DC are not passively pulsed with RNA, but in which the mRNA is introduced in the DC via active electroporation. DC were generated by culturing the adherent fraction of peripheral blood mononuclear cells in the presence of GM -CSF and IL -4 during 6 days. At day 6, the DC were harvested and electroporated with in vitro transcribed mRNA and subsequently matured for 24 hours. This leads to an average electroporation efficiency of 70%, with no significant loss of cell viability. The transgene expression remains relatively stable during 72 hours post electroporation. After maturation, the electroporated DC have acquired a fully mature phenotype ( CD14 À , CD80 + , CD83 + , CD86 + + , HLA -DR + + ) and are capable of stimulating allogeneic T cells, even at a high responder / stimulator ratio of 900 / 1. The production of IL -12 after CD40 ligation is slightly reduced compared to non electroporated DC. We compared the expression level of Mage -A3 or Lage -1b in electroporated DC and tumor cell lines by RT-PCR, and it is shown that the level of expression in the electroporated DC is comparable with the endogenous expression level in tumor cell lines. The mRNA -electroporated DC could be frozen in aliquots of 10*10 6 cells and thawed without loss of viability or function. From these results, we conclude that mRNA electroporation is a powerful tool for gene delivery into DC without any safety concern and these mRNAelectroporated DC could be ideal candidates for use in tumor vaccines.
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Gene delivery into dendritic cells for antigen -specific T cell stimulation Dendritic cells ( DC ) represent a particularly attractive cell type for use in immunotherapy of diseases. DC get exposed to a variety of pathogens such as viruses and bacteria, which they capture through specific cell surface receptors. Our experiments capitalise on using such surface receptors for gene delivery into DC by receptor mediated endocytosis.
Gene modified DC were generated by targeting cell surface bound receptors with chimeric ligand / DNA binding transfer complexes. DC abundantly express mannose receptor and adenovirus ( Ad ) receptor. Accordingly, mannose polyethylenimine ( ManPEI ) conjugates were synthesized that consist of the receptor binding moiety mannose and the polycation PEI that binds and condenses DNA, and following uptake into cells facilitates exit from the endosomal compartment. Additionally, Ad / PEI / DNA transfection complexes were also generated that contain plasmid DNA bound to the outside of adenovirus particles by PEI with adenovirus particles serving as ligand for receptor specific uptake.
Both ManPEI / DNA and Ad / PEI / DNA complexes were effective in delivering DNA into human and mouse DC. Employing these gene delivery systems DC were generated that express cDNA encoding chicken ovalbumin ( OVA ). Such DC effectively induced IL -2 production and proliferation of T cells from OVA specific TCR transgenic mice in vitro. Different formulation of ManPEI / DNA and Ad / PEI / DNA transfer complexes are currently being studied that elicit antigen specific CD4 and / or CD8 T cell activation and allow, by modification of antigen encoding cDNA, selective modulation of immune responses.
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Challenges associated with adenovirus -mediated p53 gene transfer in a model of minimal residual cancer in the muscle bed Clinical studies have revealed that tumours may recur at the operative site frequently due to residual disease remaining in the body after treatment. Destruction of these remaining malignant cells, which can be present in both mucosal and deep muscle margins, are ideal targets for p53 -mediated gene transfer techniques. Most preclinical studies have used subcutaneous tumour models in nude mice, but it is anticipated that transduction of tumour cells in the dense muscle bed in immunecompetent hosts may be more difficult. To address this point a new rodent model of minimal residual cancer was established by implanting PDVC57B tumour cells, harbouring a p53 gene mutation, into the muscle of syngeneic immune -competent C57Bl / 6 mice to produce multiple nests of tumour. Subcutaneous tumours and a subcutaneous model of minimal residual disease were used as comparators. In vitro studies established the suitability of PDVC57B for the development of in vivo models to test the effects of adenoviral -mediated p53 gene transfer. However, although 5Â10 10 viral particles of Ad5CMV-p53 was sufficient to cause tumour cell death as detected by morphology and TUNEL staining in the subcutaneous model, and prevent tumour outgrowth of residual tumour cells in the lax subcutaneous tissue, it was not effective in the dense muscle bed tumours. The most likely explanation, based on the pattern of beta -galactosidase ( -gal ) expression, is that insufficient vector reaches the tumour nests in the muscle. -gal activity in subcutaneous model was approximately 20% following a single administration of 5Â10 10 viral particles, however, in the muscle bed model activity in the tumour cells was low, typically < 3%. These studies highlight the need to improve delivery of adenoviral -mediated gene transfer to tumour nests at less accessible sites, for example by systemic delivery, or to use combination therapies, without overlapping toxicities to increase selective and specific tumour cell killing.
PD -37 Development of gene therapy vectors for combination radiotherapy of cancer
Simon Scott, B. Marples, S. Bourne, A. Walker and M. C. Joiner Gray Laboratory Cancer Research Trust. The combination of gene therapy with radiotherapy offers exciting prospects for the future treatment of cancer. We have been developing radiationresponsive vectors suitable for use with clinical radiation doses. The vectors contain radiation -responsive CArG elements from the human Egr1 gene regulating expression of heterologous genes. The radio -induction of these novel synthetic promoters was assayed using the green fluorescent protein ( GFP ) reporter gene. Clinically relevant doses of ionising radiation ( 1 -3 Gy ) were able to induce GFP production 2 -3 -fold. These promoters were then used to drive the herpes simplex thymidine kinase / ganciclovir ( HSVtk / GCV ) suicide gene system in tumour cell killing assays ( Marples et al., 2000; Gene Therapy 7:511 -517 ) . In order to improve efficacy, we have recently examined the effects of CArG number, sequence and spatial arrangement. This data has enabled us to define some important criteria for CArG induction response at these low doses.
To provide long -term, constitutive gene expression and to markedly enhance the level of tumour cell killing a novel ''molecular switch'' scheme based on Cre / Lox recombination was adopted. This resulted in a substantial enhancement of GFP production and tumour cell killing ( Scott et al., 2000; Gene Therapy 7:1121 -1125 . To further improve the overall efficiency of the switch scheme, the original dual -plasmid system has now been replaced with a single vector bearing all the active components. This vector is currently being tested in a U87 glioblastoma xenograft model. MRC, LMB, Cambridge CB2 2QH. E-mail address: mahvash.tavassoli@kcl.ac.uk. Both p53 and p16 / INK4a genes play important roles in the control of cell cycle checkpoint G1. Loss of function of these genes has been associated with the development of many types of cancers. The majority of head and neck cancer cell lines have mutant p53 and p16 / INK4a genes. We examined if the expression of one or both of these genes is required to induce growth arrest or apoptosis in head and neck cancer cell lines lacking the function of both genes. p53 was expressed either in an inducible vector, p53 -ER whereby the hormone binding domain of the oestrogen receptor is fused to wild type p53 or constitutive CMV promoter in pCB6 + -p53. p16 / INK4a was expressed using an inducible Lac Switch p16 / INK4a as well as the constitutively expressed pCMVp16 / INK4a plasmid. p53 activation by tamoxifen resulted in strong induction of p21 but failed to induce significant growth arrest and / or apoptosis in head and neck cancer cell lines. Furthermore, wild -type p53 delayed the onset of apoptosis induced by cisplatin. Expression of p16 / INK4a alone resulted in increased level of hypophosphorylated pRB and induced a G1 arrest in HN5 and HN6 but not H1299 lung cancer cells. Activation of p16 / INK4a in cells which were already transfected with wild -type p53 induced apoptosis in HN5 and HN6 cells. However, if p53 was induced at a late stage, p16 / INK4a expression was unable to induce apoptosis. Our data shows that HN5 and HN6 are resistant to p53 -dependent growth suppression but p53 function is necessary to enable p16 / INK4a to activated cellular apoptotic mechanisms.
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Efficient induction of cell cycle arrest and apoptosis in human hepatic cells by E1B gene -deleted adenovirus through p53 independent pathway Primary liver cancers remain one of the most common malignancies worldwide. The annual incidence of liver cancer is approximately 1 million cases. Several etiologic causes have been described for hepatocellular cancer, including a strong association with hepatic virus, alcoholic cirrhosis and environmental toxins. Surgical resection remains the mainstay of therapy although chemotherapy adds to the overall survival of patients in whom a curative resection is impossible. Therefore, development of novel therapeutic strategies of hepatic cancer is needed. Recently, E1B deleted adenovirus ( dl1520 ) gene therapy for patients with primary and secondary liver tumors were developed.
In the present study we have tested the effect of E1B deleted adenovirus ( dl1529 ) gene on the cell cycle of normal and cancer hepatic cells. The normal hepatocytes ( Chang ) and hepatocarcinoma cell lines; HepG2 ( p53 wild -type ), PLC / PRF ( p53 mutant ) and Hep3B ( p53 deleted gene ) were used. Our results indicated that transfection of E1B gene -deleted adenovirus to the above cells, was significantly reduced proliferation of the cells without affecting the release of LDH. Interestingly, 24 h after transfection the cells have p53 wild -type ( Chang and HepG2 ) were arrested on S and G2 / M phases of the cell cycle, were the cells have p53 mutant ( PLC / PRF and Hep3B ) arrested on G2M phase. Moreover, 72 h after transfection, apoptosis was induced in the hepatic cells. These studies indicated that E1B gene -deleted adenovirus inhibit hepatic cell proliferation, induce cell cycle arrest that followed by induction of apoptosis. These effects are mediated by p53 independent pathway. Further studies are needed in order to clarify the molecular mechanisms of E1B gene -deleted adenovirus in hepatic cells.
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Modulation of the c -myc proto-oncogene in cutaneous melanoma The c -myc proto -oncogene plays a key role in cell proliferation, malignant transformation and apoptosis. Previous work at RAFT demonstrated that cmyc expression levels are an accurate prognostic marker in melanoma. Cmyc is therefore regarded as a potential target for corrective gene therapy. Antisense oligonucleotides complementary to the c -myc translation initiation site were constructed. These reduced growth of A375M cells in vitro. This reduction could be correlated with decreased c -myc gene activity. Immunodeficient mice were then implanted with A375M cells and treated with antisense. Following treatment, tumours had developed in 21% of the treated group compared to 73% in groups treated with a scrambled oligonucleotide and 100% in the saline treated controls.
Ribozymes are a catalytic RNA molecule that cleaves mRNA and are thus more efficient than antisense oligonucleotides. A ribozyme was constructed targeting the same region of mRNA as the antisense. A375M melanoma cells were transfected using liposomes and growth was assessed using a MTS growth assay. C -myc expression was measured with immunostaining and flow cytometry. The ribozyme did not reduce growth or c -myc expression. Further ribozymes targeting different regions of the cmyc gene are being assessed.
Reducing c -myc expression decreases melanoma cell growth. Oligonucleotides are an effective method in vitro and in vivo. Development of ribozymes may provide a useful new gene therapy for the treatment of melanoma.
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Adenovirus -mediated gene delivery of tissue inhibitor of metalloproteinases -3 ( TIMP -3 ) inhibits melanoma growth in vivo Matti Ahonen, Andrew H. Baker, Sarah George, Ulpu Saarialho -Kere and Veli -Matti Kähäri Centre for Biotechnology, University of Turku, Turku, Finland; Bristol Heart Institute, Bristol Royal Infirmary, Bristol, United Kingdom; Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland and Department of Medicine and Therapeutics, University of Glasgow, Glasgow, United Kingdom. Melanoma is a tumor with high potential for invasion, metastasis and growth. These phenomena involve regulation by secreted matrix metalloproteinases ( MMPs ), capable of degrading all components of the extracellular matrix. We have recently shown that adenovirus -mediated gene delivery of secreted metalloproteinase inhibitor, tissue inhibitor of metalloproteinases -3 ( TIMP -3 ) inhibits invasion and induces apoptosis in melanoma cells in culture. Here we have studied the effect of adenovirusmediated gene delivery of TIMP -3 ( RAdTIMP -3 ) and TIMP -1 ( RAd-TIMP -1 ) on melanoma tumor growth in vivo in SCID / SCID mice.
Human metastatic melanoma A2058 cell line was used in all experiments. A2058 cells were transduced ex vivo at 100% transduction efficiency, and injected s.c. in SCID / SCID mice. No tumor formation was detected with RAdTIMP -3 infected cells, whereas RAdTIMP -1 infected cells formed tumor in 60% ( 3 / 5 ) of mice and RAdlacZ infected cells in 100% ( 5 / 5 ) of mice. Next RAdTIMP -3 and RAdTIMP -1 ( 1.4Â10 9 pfu each ) were injected into pre -established ( 50 -100 mm 3 ) tumors in vivo 3 consecutive daily injections. Marked inhibition of tumor growth was observed in RAdTIMP -3 injected tumors. Injection of tumors with RAdlacZ and RAdTIMP -1 did not markedly alter tumor growth as compared to control tumors injected with PBS. Expression of TIMP -3 and TIMP -1 was detected as early as 1 day after 3 consecutive injections and was associated with reduced gelatinolytic activity as detected by in situ zymography. TIMP -3 expression was associated with increased apoptosis and reduced angiogenesis. These results indicate that adenovirus -mediated gene delivery of TIMP -3 results in marked inhibition of human melanoma tumor growth in SCID / SCID mice and validates its further exploration in development of gene therapy for malignant melanoma.
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Clinical phase I trial: therapy for feline fibrosarcoma with recombinant adenovirus vectors expressing human IL -2 and feline IFN -g T. Brill, H. Homann, S. Wieland, J. Ludwig, R. Köstlin, B. Gansbacher, J. Hirschberger Inst. f. Exp. Oncology, TU Munich, Germany. Feline fibrosarcoma was evaluated as a model for the adjuvant therapy of cancer with IL -2 and IFN -g. Feline fibrosarcoma is a common tumor, which relapses locally in about 70% of the cases.
Adenovirus ( E1 À / E3 À Ad5 TRANSGENE, SA ) expressing human IL -2 and feline IFN -g were injected in the tumor bed at five days after removal of the tumor.
After dose escalation with 1Â10 7 , 5Â10 7 and 1Â10 8 ( n = 4 each ) a dose of 5Â10 8 ( n = 8 ) resulted in detectable plasmatic IL -2 concentrations ( maximum of 160 to 580 pg / ml at d3 ) and was well tolerated by the cats and will be used in the phase II clinical trial.
Adverse events were seen in the group receiving 5Â10 8 iu. All Adenovirus vector injected cats developed fever vs. 1 of 8 in the control group. Statistical analyses proved the elevation of body temperature and an elevation of the liver transaminase AST to follow a dose dependent manner. A mild reduction of the lymphocyte counts between d2 and d4 were measured. Tumor free survival time was elongated in the group with the highest vector dose but due to low numbers statistical significance could not be reached.
The dose of 5Â10 8 iu, which induced measurable plasmatic IL -2 concentrations and only minor side effects in cats, is exactly the dose used for mice. The infectability of feline cells seems to be higher than that of murine cells.
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Transfer of cDNA of the human interleukin 2 gene by a recombinant, replication -defective, adenovirus administered under surgical control in patients with unresectable digestive adenocarcinoma: a phase I study Biomolecular Laboratory, CAC Léon Bérard, 69008, Lyon, France. Background: Survival rates of unresectable digestive adenocarcinoma remain poor in spite of encouraging tumor response rates of systemic chemotherapy. Systemic immunotherapy with interleukin -2 ( IL -2 ) has been evaluated but revealed an high toxicity.
Aim of the study: This protocol was designed as a phase I -II trial to evaluate the safety, the clinical and biological effects of a single intratumoral administration of recombinant adenovirus ( type 5 ) containing cDNA for the human IL -2 gene ( TG 1021 ) in patients with unresectable digestive adenocarcinoma.
Material and Methods: The protocol was designed as an open, non randomized, monocentric, dose escalating study. Ten patients ( 4 males, 6 females ) aged 26 -61 years ( mean age 48.4 yrs ) with unresectable digestive adenocarcinoma ( 3 colon with diffuse liver metastases, 7 pancreas ) were included at three different dose levels ( 10 7 , 10 8 , 10 9 pfu ). Administration of TG 1021 was intratumoral, performed under surgical control, in a specific operating room ( with TL2 protection ) through multipoint injection.
Results: Results of the neutralising antibodies showed an humoral immune response with a titration higher than 1 / 400 in 3 patients. There was a trend of production of IL -2 in 2 patients. Administration of TG 1021 was well tolerated up to maximal tested dose ( 10 9 pfu ). Adverse events were generally considered as related to the underlying disease. As regard to risk of vector dissemination, detection of infectious particles of the vector was positive in blood for 6 patients on Day 0, and detection of the recombinant vector DNA was positive in all but one patient on Day 0. Samplings from all other localisations were negative except for 2 patients ( positive pharyngeal culture for one patient and positive draining fluids by PCR for another on Day 0 ). One patient died on Day 13 and seven patients died during the long term follow -up ( Month 2 to Month 14 ). All deaths were considered by the investigator as unrelated to study drug and due to disease progression. One patient is still alive at month 37 after having undergone liver transplantation. There was no significant tumor response according to the standard WHO oncology criteria. One patient showed an initial regression of the subpancreatic tumor with improvement in general status and received a second TG 1021 administration after 6 months ( 10 8 pfu ) without further response to treatment.
Conclusion: Unresectable digestive adenocarcinoma was a good model to evaluate intratumoral injection of TG 1021. Clinical, biological and immune tolerance were acceptable with no toxicity observed at the three dose levels tested. Based on absence of viral dissemination observed, patient isolation could be reduced in future studies.
PD -44
Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin -12 /B7.1 genes panied by massive infiltration of T lymphocytes. In these tumors, we found increased levels of CD4 + and CD8 + T cells and interferon -. In continuously growing tumor nodules injected with the control vector or in nontumoral liver, no effect was detected. In the fifth animal, monitored for long -term antitumor efficacy by magnetic resonance imaging ( MRI ) after intratumoral vector administration by MRI guidance, the tumor was almost completely eliminated ( !95% ) 7 weeks after treatment. Adenovirusvector -based immunotherapy appears to be an effective treatment of large nontransplanted ( orthotopic ) tumors that acquire malignant characteristics in a stepwise process, reflecting the real -world scenario of hepatocellular carcinoma in humans.
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Syngeneic fibroblasts secreting murine IL -12 in an immunocompetent mouse model of ovarian cancer: a balance between tumour-inhibitory and tumourpromoting activities Fibroblasts have been proposed as cytokine delivery vehicles for ex vivo cancer gene therapy strategies because of their ease of culture, low migratory potential and nontumorigenicity, as compared to tumour cells.
Our aim was to study the effect of syngeneic fibroblasts secreting murine IL -12 in the immunocompetent ID8 mouse model of ovarian cancer.
We inoculated female C57BL / 6 mice i.p. with ID8 tumour cells in one flank ( day 0 ) and treated these mice i.p. either with unmodified MC57 fibroblasts, or fibroblasts secreting mouse , in the other flank. Control groups of mice were left untreated. Several treatment regimens were compared: single injection of live cells at day 0, 13 or 21, and multiple injections at days 0, 13, 21 and 63 of either live or lethally irradiated cells. Survival analysis showed that the best therapeutic effect was obtained treating with MC57 mIL -12 at day 0. The therapeutic effect of a single injection of live MC57 mIL -12 decreased with increasing time between tumour cell inoculation and treatment. Multiple injections of either lethally irradiated or live MC57 mIL -12 led to significantly increased survival of mice previously injected with tumour cells. However, we also noted that unmodified MC57 fibroblasts showed tumour -promoting activity. Sections of tumour nodules stained with HES revealed that those from mice treated with MC57 were more vascularised than those obtained from mice treated with MC57 mIL -12, or left untreated. Furthermore, these fibroblasts secrete the angiogenic factors IL -8 and VEGF.
Taken together, our results suggest that MC57 mIL -12 fibroblasts not only produce antitumoral mIL -12, but also endogenous tumour promoting factors, such as angiogenic factors, thus partially masking the effect of mIL -12. Therefore, cellular vehicles delivering cytokines for cancer treatment need to be carefully selected for the absence of direct and indirect influence on tumorigenesis.
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Anti -tumour activity of T cells expressing chimeric receptors which incorporate both primary and costimulatory signalling sequences These chimeric receptors have been tested in cell killing and in specific cytokine production assays in vitro, and the most potent construct has demonstrated efficacy in an in vivo model of tumour immunotherapy.
Expression of chimeric receptors was achieved in human peripheral blood lymphocyte blasts by infection with recombinant adenovirus. Antitumour specificity was conferred by an engineered human single chain Fv derived from P67.6 ( a monoclonal antibody with specificity for human CD33 ). These effector cells were premixed with tumour target cells ( NS0 cells expressing human CD33 ) at an E:T ratio of 1:1 immediately before subcutaneous administration to the flank of nude mice. Animals were monitored for tumour growth daily, and tumour size was measured using calipers. In the control group, all ten animals developed tumours by day 25, but in the group which had received PBMC effector cells expressing the optimised chimeric receptor construct, all ten animals remained free of tumours for greater than 90 days.
The in vivo data complements the in vitro observations already reported, and confirms the beneficial effects attributable to the inclusion of costimulatory signalling domains in the design of chimeric receptors for the adoptive immunotherapy of cancer.
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Melanoma tumor growth prevention by vaccination with genetically modified B16 tumor cells The stimulation of the immune system can develop a rejection of different substances including antigens from tumor cells. This process can be achieved with mediators in the immune response, as cytokines. We have tested two different cytokines: GMCSF and IL -4 since they are involved in CTL and humoral immune response respectively. We studied the advantages of alone administration or the coadministration. GMCSF and IL -4 were transfected to B16 cells ( murine melanoma ) in order to obtain clones with a continuous production of cytokines. The irradiated cells ( 150 Gy ) were s.c. injected to mice in two doses of vaccines ( 0.2 or 1 mill. cells / dose ) before challenging with 10 5 tumor cells ( nontransfected nonirradiated B16 cells ). Mice were followed with a continuous assessment of tumor volume and mice survival. Blood samples ( 200L ) were taken from the tail vein overtime after vaccination. The results were that the administration of cells with higher GMCSF production mediates 100% mice survival. When we reduce the doses 5 times, the survival is 80% of the mice. IL -4 alone doesn't produce a protective effect against tumor. In addition, the covaccinations with GMCS plus IL -4 modified cells not only no reduce the mortality of mice, but minimize GMCSF effect. Our conclusions are that mice vaccination with irradiated and genetically modified cells producing GMCSF, significatively prevent of wild type tumor growth and progression, which results in mice survival. IL -4 genetically modified cells have not this effect, and a coadministration of both cytokines does not improve GMCSF alone effect against tumor. Supported by IMTEFA / 2000 / 41 grant.
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Modifying low -dose hyper-radiosensitivity by ribozyme mediated down -regulation of poly( ADP -ribose ) polymerase Background: In many glioma cell lines, acute doses of radiation below $50 cGy are more lethal per unit dose than higher doses. These dual phenomena, termed low -dose hyper -radiosensitivity ( HRS ) and increased radioresistance ( IRR ), may reflect dose -dependent changes in DNA repair mechanisms. Abrogation of the IRR response by chemical inhibitors of PARP support its role in the HRS / IRR phenomenon.
Procedures: We have generated a plasmid vector encoding a ribozyme targeted against PARP mRNA at a site immediately downstream from the start codon, and a green fluorescent protein. Negative control vectors have also been cloned. T98G human glioma cell lines were transfected with these vectors. After 72 hour incubation, transfected cells were selected by FACS. The effect of the ribozyme on PARP protein and activity levels is being assessed by Western blotting and NAD + incorporation assays respectively. Established low -dose cell survival assays will be used to generate survival curves.
Findings: Transfection of T98G glioma cells has been achieved, Western blots and cell -survival assays are in progress, and a PARP activity assay is in development. Changes in low -dose survival of ribozyme -transfected cells, compared with untransfected and negative control -transfected cells, will be compared with changes in PARP expression and activity. Future studies will utilise cell lines with similar radiosensitivity but varying levels of the HRS phenomenon. Results will elucidate the role of PARP in low -dose HRS in gliomas.
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Expression of insulin -like growth factor binding protein -4 (IGFBP -4) following direct gene transfer into muscle Myofibres have been shown to take up plasmid DNA and to subsequently express the exogenous gene over a prolonged period following intramuscular injection. We constructed an expression plasmid containing IGFBP -4 cDNA and a myosin light chain enhancer element, under the control of the CMV promoter and assessed the direct injection method as a means of systemically delivering IGFBP -4. IGFBP -4 binds to IGFs, which are potent mitogens, with high affinity. Unlike other IGF -BPs, IGFBP -4 is wholly inhibitive in its activity. The systemic expression of IGFBP -4 could be a potential therapy for primary colorectal tumours as well as metastases.
Initial expression studies were performed in cell culture in which IGFBP -4 was over expressed in the colorectal cancer cell line ( WiDr ). There was an increase in apoptosis and a significant decrease in the number of viable cells.
In vivo expression of IGFBP -4 in the tibialis anterior muscle of nude mice was detected ten days after injection by reverse transcription polymerase chain reaction ( RT-PCR ) and western blotting. Real time quantitative PCR was used to determine levels of transgene expression. Results indicated that the levels of expression between animals ( n = 5 ) fell within normal distribution ( Mann -Whitney U test ).
We conclude that the IGFBP -4 construct containing a CMV promoter and MLC enhancer can provide reproducible levels of gene expression. This offers a potential method of targeting IGFs, which play a critical role in tumour cell proliferation.
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Purification of an infectious Moloney murine leukaemia virus cancer gene therapy vector using hydroxyapatite We have therefore concentrated on identifying a scalable process that purifies replication incompetent gene therapy vectors based on Moloney murine leukaemia virus ( MoMuLV ). Based on a literature survey, we studied two commercially available chromatography media: MatrexÒ CellufineÔ Sulfate ( MCS; Millipore ) and Macro -PrepÒ ceramic hydroxyapatite ( MCHT2; Bio -Rad ).
In batch experiments, our results show that MCHT2 is superior in its ability to adsorb MoMuLV as compared to MCS. Further experimentation with MCHT2 shows that infectious MoMuLV can be eluted from this medium, using 300 -400 mM phosphate buffer pH 6.8. The recovery in these experiments is about 40%, with an increase of $30 fold in the titre per mg protein in the fraction eluted with 400 mM eluent. Similar results were obtained using a liquid chromatography system.
These results show that MCHT2 may be a useful step in the purification of gene therapy vectors based on MoMuLV, especially if recovery and purification can be further optimised.
This research was supported by a BBSRC Link grant.
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Potential for transcriptional targeting in bladder cancer -the uroplakin Ib gene promoter The uroplakins ( UP ) are 4 distinct genes whose products form plaques that are unique to the luminal membrane of terminally differentiated bladder epithelial ( urothelial ) cells. The UPIb gene is highly expressed in around 50% of muscle -invasive bladder cancer primaries and lymph node metastases. Thus, the UPIb promoter could provide a means to target therapeutic gene expression in bladder cancer and the aim of this study was to characterise the promoter of the human UPIb gene.
UPIb full -length 5 0 UTR and the transcription start site were mapped using 5 0 RACE and ribonuclease protection assays. Functional characterisation of 5 0 flanking genomic DNA was performed by transient transfection of UPIb -luciferase reporter constructs into UPIb -expressing and nonexpressing urothelial and nonurothelial cell lines of normal and tumour derivation.
Results showed that the UPIb proximal promoter is TATA -less, with multiple transcription initiation sites lying within a short noncoding exon 1. A short region ( 85 bp ), located just upstream of UPIb exon 1, conferred strong transcriptional activity in a range of bladder cancerderived cell lines. This activity was greater than that generated by the SV40 basal promoter. The same UPIb construct had weaker transcriptional activity in cultured primary human skin fibroblasts. Longer UPIb constructs generated lower luciferase activity but maintained differential cell type specificity.
A strong functional human UPIb proximal promoter has been identified that has differential transcriptional activity in urothelial and fibroblast cell types. The definition of urothelium -specific transcription regulatory elements should find application in targeting gene therapy strategies for bladder cancer. Genetically retargeted adenovirus ( Ad ) can be constructed by replacing the fiber knob with an external trimerisation motif followed by a new cell binding ligand. Any ligand added to the fiber must be able to fold correctly in the reducing environment of the cell cytosol and nucleus. We have now identified a group of suitable ligands called affibodies. Affibodies are derived from the IgG binding Z domain of Staphylococcal protein A, which has a stable three -helix bundle structure devoid of disulfide bridges. Through combinatorial engineering of the domain surface, libraries can be constructed from which novel binding specificities to desired targets can be selected. Here, two protein ligands capable of selective binding to IgG and IgA, respectively, have been used to construct retargeted Ad.
Ad fibers with the IgG binding ligand ( Zwt ) alone or in combination with the IgA binding domain ( ZIgA ) were constructed and showed good nuclear transportation, trimerisation and ligand binding when expressed in COS7 cells.
Recombinant fiber genes were rescued into the Ad 5 genome for virus production in a packaging cell line ( 293 cells ) stably transfected for surface expression of Fc fragment from human IgG to serve as ligand for Zwtdecorated Ad. The new specificities of the retargeted Ad were verified by dot -blot and FACS analysis. Interestingly, two different motifs binding to different ligands could be expressed in the same fiber with retained individual binding specificities.
This study shows that affibodies can be used to retarget adenovirus. In addition it is possible to construct Ad re -targeted to two ( or more ) new receptors by incorporating different affibody ligands. By selection of affibodies with novel binding specificities gene -therapy targeted to a wide range of cell types may be achieved.
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Production of an adenovirus -5 b -Gal vector in suspension culture of PER.C6 cells Israel Oyebade*, Steve McGowan, Catherese Fahey, Enda Moran GlaxoSmithkline, South Eden Park Road, Beckenham, Kent BR3 3BS, UK. The development of a manufacturing process for the production of an Adenovirus vector encompasses raw material issues as well as process issues. The choice of growth medium is an important factor as the growth medium must be able to sustain both cell growth and virus production. Process parameters such as pH, temperature and dissolved oxygen must be considered carefully in order to achieve a reproducible process. The poster describes an 8 -day scale -up production process for Adenovirus -5 b -Gal vector in a suspension culture of PER.C6 cells in a commercially available medium. Infecting at MOI = 1, it is possible to achieve virus titre ranges of 108 -109 TCID50 / mL in a 10 L culture vessel.
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Development of a large scale recombinant adenovirus purification process James Walford, Sohail Chohan, David Young GlaxoSmithKline, South Eden Park Road, Beckenham, Kent, UK. Downstream development of a recombinant adenovirus purification process usually involves cell lysis, a primary capture chromatography step and subsequent concentration and product polishing steps. Choices of cell lysis method ( chemical or mechanical ) have been shown to have an impact on downstream processing.
Screening of chromatography adsorbents has indicated that the type of matrix selected is critical for recombinant adenovirus purification.
A rapid capture step has been chosen with high virus capacity ( > 1Â1012 p / mL gel ), providing good selectivity and recovery of infectious particles.
A gel filtration step completes the purification and buffer exchanges virus intermediate into a formulation buffer suitable for freeze -drying. This process has been shown to be robust, reproducible and scaleable ( from analytical to manufacturing scale ).
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The cytotoxic effect of E1B55kDa -mutant adenovirus on human hepatocellular carcinoma cell lines It has been suggested the E1B55kDa mutant adenovirus dl1520 can selectively kill p53 -deficient human tumor cells. In this study, we examined the cytotoxic effect of dl1520 on 9 human hepatocellular carcinoma ( HCC ) cell lines with different p53 genetic and functional status. The cell lines used in this experiment were established in our laboratory. The results showed that HCC cell lines with deleted or mutant p53 gene and reduced p53 transcriptional activities were more susceptible to dl1520 -induced cytolysis. Hep3B ( p53 -null ) and HepG2 ( p53 -wt ) cells were arrested at G2 / M phase when cytolysis occurred. Cyclin -dependent kinase inhibitor ( CDKI ) p21 Waf -1 / Cip -1 was down -regulated 24 h after dl1520 infection in HepG2 cells and increased when cytolysis occurred. No p21 expression was detected in Hep3B cells. DNA fragmentation was found in both Hep3B and HepG2 cells after dl1520 infection. Bax expression increased in dl1520 infected HepG2 cells but not in Hep3B. Notably, three Bax -like proteins, molecular weight around 40 to 80 kDa, accumulated 48 h after adenovirus infection in Hep3B cells but not in HepG2. These results indicate that the susceptibility of HCC cells to dl1520 -induced cytolysis is related to both p53 genotype and functional status, and is mediated by cell cycle disturbance and apoptosis. Development of antitumor specific virus using gene modification technology may provide a novel strategy for treatment of 
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Tumor cells co-transduced with chemokine and costimulatory molecule developed long -term immunity against wild -type tumor An important aspect of immunity is the recruitment and accumulation of lymphocytes into target tissues where antigens are localized. Chemokine family members play an important role for recruiting the selected populations of leukocytes through chemotactic action. A set of costimulatory molecules on tumor cell surfaces is essential for T cell activation with production of cytokines. Immunogenic potential of tumor cells can be enhanced through defined molecular modifications. Modification of tumor cells to express co -stimulatory molecules as B7 -1, 4 -1BBL or chemokines as MIP -1 or RANTES can be used as cellular vaccines to elicit antitumor specific immunity that is effective in eradicating established tumors in animals. Present study seeks to further develop a combination gene therapy protocol with retroviral vector mediated co -transfection of a co -stimulatory gene and a chemokine gene for treatment of mouse hepatocellular carcinoma. Single gene transfectants of mouse hepa1 -6 cells, mMIP -1 ( mouse MIP -1 ), mRANTES ( mouse RANTES ), m4 -1BBL ( mouse 4 -1BB Ligand ) and mB7 -1( mouse B7 -1 ), and cotransfectants, mMIP -1 plus m4 -1BBL or mB7 -1, and mRANTES plus m4 -1BBL or mB7 -1, have been successfully established in our laboratory. The expression of mMIPCancer Gene Therapy, Vol 8, No 11, 2001
1 or mRANTES was confirmed by immunohistochemistry and the expression of m4 -1BB L or mB7 -1 was confirmed by FACScan analysis. The transfectants showed no expression of m4 -1BB L, mB7 -1, mMIP -1 and mRANTES were as controls. When m4 -1BBL or mB7 -1 modified tumor cells were used as stimulators of allogeneic spleen lymphocytes in mixed lymphocyte -tumor cultures ( MLTC ), T-cell proliferation was significantly increased. Chemotaxis assay showed that the cells modified with mRANTES or mMIP -1 can secrete substantial levels of chemokine activity for mouse spleen lymphocytes, while control transfectants showed no chemotactic activity. Neither did the production of mRANTES, mMIP -1, m4 -1 BB L or mB7 -1 alone nor did the production of chemokine plus co -stimulatory molecule by transfected clones affect their proliferation and growth in vitro. When injected subcutaneously ( s.c. ), transfectants producing mRANTES or mMIP -1 alone had a slow tumour growth and the tumor cells expressing m4 -1 BB L or mB7 -1 alone showed reduced tumor formation. Tumor formation rate in mice inoculated with m4 -1BBL expressing cells, mB7 -1 expressing cells or with the cells producing both chemokine and co -stimulatory molecule was 25%, 62.5% and 0% respectively. When the mice were inoculated with the mixture of wt hepa1 -6 and vaccine cells producing both chemokine and co -stimulatory Flt3 ligand ( FL ) can promote antitumor activity through inducing a profound expansion of mature DC subsets in various tissues in mice, consequently augmenting antigen presentation. While antibody mediated CTLA -4 blockade can augment host antitumor responses by prolonging T cell activity and / or facilitating antigen -specific T cell costimulatory activation. However, it has been shown that these two treatment regimens alone cannot induce complete tumor regression in weakly immunogenic tumors. In the present study, we test the hypothesis that FL -transduced tumor vaccine therapy, which expands DCs in vivo, combining with CTLA -4 blockade, should enhance antitumor responses in the treatment of poorly immunogenic tumor.
A murine hepatic cancer cell line Hepa1 -6 was used to establish an experimental mammary carcinoma. Six -to 8 -week -old female C57BL / 6 were injected s.c. on the nape of the neck with 1Â10 6 tumor cells. Tumor growth was monitored by measuring bisecting diameters with vernier calipers. The FL -expressing Hepa1 -6 derivative was prepared by Lipofectamin transfection with linear plasmids containing the murine soluble form FL gene driven by CMV promoter. For vaccine regimen, FLexpressing cells were irradiated with 5000 rad by using a 60 Co -source irradiator. 1Â10 6 irradiated cells were used as vaccines implanted to the contralateral flank from the parental tumor challenge on day 0, 3, 6. Anti -CTLA4 was prepared through protein G -purification of supernatants from the 9H10 hybridoma line. Antibody concentrations were quantified by UV spectrophotometer. On day 4, 7 and 10 subsequent to tumor challenge, mice were injected i.p. with 100 g of anti -CTLA -4. 30 days after tumor regression, tumor -free mice were rechallenged with 1Â10 6 unmodified tumor cells and tumor growth was monitored.
In our experiments, mice treated with FL -expressing vaccine or anti -CTLA -4 alone all showed delayed tumor growth. 60% ( 3 / 5 ) of mice treated with FL -expression vaccine displayed complete tumor regression and were immune to rechallenge. CTLA -4 blockade regimen conferred little effectiveness against Hepa1 -6 tumor ( 2 / 6 ). While 100% ( 5 / 5 ) mice treated with combination therapy of anti -CTLA -4 + FL -expressing vaccine resulted in complete regression of tumors, and also rejected the rechallenge.
These results suggest that FL -expressing vaccine can be used as an 
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Multiple furin recognition sequences enable more cleavage of the chimeric proteins encoded by the fusagene vectors Jie Jiang, Joop Gaken, Farzin Farzaneh Department of Molecular Medicine, GKT School of Medicine, King's College London, The Rayne Institute, London SE5 9NU, UK. The expression of multiple gene products is a requirement in a number of gene therapy protocols. In some situations, equimolar amounts of two or more gene products are required. However, these cannot be easily achieved with the currently available vectors. Here, we describe a novel approach for expression of multiple gene products from a single cistron. Specifically, sequences encoding Arg -X -Arg / Lys -Arg have been incorporated between in -frame cDNA sequences encoding different proteins and cloned into retroviral vectors. The chimeric proteins are translated as single fusion proteins which are cleaved and processed by furin, an endoprotease in the Golgi, into their constituent, active, components. The efficiency of protein cleavage was found to be dependent on the expression of furin in different cell types. When the transfected cells were cotransfected with expression vectors encoding furin, a more efficient cleavage of the chimeric proteins was observed. Furthermore, multiple furin recognition sequences were incorporated between the encoded polypeptide sequences, resulting in increased expression of gene products ( eg. mouse IL -2 and IL -4 ) as analysed by ELISA and Western blots. This may be due to better exposure of the cleavage sites to the furin. These results show that the fusagene strategy enables the coordinated expression of multiple gene products from a single, monocistronic, expression cassette. Furthermore, the levels of expression can be regulated by introduction of multiple furin sites. We are currently investigating the influence of different furin recognition sequences on the efficiency of cleavage.
PD -59
A new strategy for development of cytoplasmic fusagene vectors CONFERENCE ABSTRACTS IRES elements are used, the first strategy is not suitable for expression of
